BioSpace News Archive

NeuroSense Therapeutics Ltd. announced that it has opened an EU Office as well as been granted the Small and Medium-Sized Enterprise status by the European Medicines Agency, which offers significant benefits leading up to and following drug regulatory approval.

Pi-Cardia Ltd. announced today the successful completion of its ShortCut™ Pivotal Study enrollment. ShortCut™ is the world’s first dedicated device designed to split the leaflets of pre-existing valves to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk of coronary obstruction.

Tivic Health® Systems, Inc. announced that it has received notice from The NASDAQ Stock Market LLC informing Tivic that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The NASDAQ Capital Market and that it is in compliance with all applicable listing standards.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Time).

Scientific Industries, Inc., the life science tool company delivering digitally simplified bioprocessing, announced the appointment of John Nicols as Strategic Advisor to the Scientific Bioprocessing senior management team.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announces a reverse share split of the Company’s issued and outstanding ordinary shares, no par value, at the ratio of 1-for-30, such that each thirty Ordinary Shares, shall be consolidated into one Ordinary Share.

Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA-targeted drug discovery at the upcoming Cambridge Healthtech Institute Discovery on Target Conference in Boston, USA, between 25 and 28 September 2023.

OnKure, Inc. today announced the appointment of Ann Howell as Vice President of Regulatory Affairs.

Hepagene Therapeutics, Inc. a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233.

Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine, demonstrating the clinical utility of its minimal residual disease Liquid Biopsy Assay in support of Genentech’s Phase 1 Clinical Trial of Divarasib.